Share on StockTwits

St. Jude Medical (NYSE:STJ) released its earnings data on Wednesday. The company reported $0.99 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.97 by $0.02, Analyst Ratings Net reports. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.38 billion.

Shares of St. Jude Medical (NYSE:STJ) opened at 65.96 on Wednesday. St. Jude Medical has a 52 week low of $38.73 and a 52 week high of $68.39. The stock’s 50-day moving average is $62.10 and its 200-day moving average is $55.93. The company has a market cap of $19.248 billion and a P/E ratio of 26.91.

The company also recently announced a quarterly dividend, which is scheduled for Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of 0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.52%. The ex-dividend date is Friday, December 27th.

STJ has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of St. Jude Medical from $62.00 to $73.00 in a research note to investors on Tuesday, January 14th. On the ratings front, analysts at Barclays reiterated an “overweight” rating on shares of St. Jude Medical in a research note to investors on Thursday, January 9th. They now have a $72.00 price target on the stock, up previously from $65.00. Finally, analysts at BTIG Research initiated coverage on shares of St. Jude Medical in a research note to investors on Tuesday, January 7th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $56.44.

St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.